Masavibart

Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

SARS-CoV-2[1].

Masavibart (ZRC3308-A7; 0-5×105 ng/mL) shows virus neutralizing ability in VeroE6/Vero CCL81 (SARS-CoV-2 infection model) cells, when in combination with ZRC3308-B10 (ratio 1:1)[1]. Masavibart neutralizes SARS-CoV-2 variants B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro, when in combination with ZRC3308-B10 (ratio 1:1) [1]. Masavibart binds to the RBD of SARS-CoV-2 S1 protein[1]. Cell Viability Assay[1] Cell Line: VeroE6/Vero CCL81 cells (SARS-CoV-2 infection model) Concentration: 0-5×105 ng/mL (in combination with ZRC3308-B10) Incubation Time: 72 h Result: Showed potent neutralization activity with an IC50 of 0.1527 ng/mL.

Masavibart (ZRC3308-A7; 0.5, 2.5, 25 mg/kg; 48 h prior to the SARS-CoV-2 infection) effectively prevents SARS-CoV-2 infection in syrian hamster, when in combination with ZRC3308-B10 (ratio 1:1)[1]. Masavibart (0.5, 2.5, 25 mg/kg; i.p.; single) shows the serum levels remaines constant without much reduction for up to 7 days, in syrian hamster [1]. Animal Model: Female syrian hamster (7 to 10-week-old; SARS-CoV-2 infection model)[1]. Dosage: 0.5, 2.5, 25 mg/kg Administration: Intraperitoneal injection; 48 h prior to the SARS-CoV-2 infection Result: Prevented SARS-CoV-2 infection when in combination with ZRC3308-B10.

[1]. Yadav PD, et al. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. Viruses. 2021 Dec 3;13(12):2424.